McDonald’s sales down amid no antibiotic announcement

Fast-food giant McDonald’s is continuing to see a downward slope in sales, posting a same-store sales drop of 4 percent in February in the United States and a 1.7 percent drop globally.

While sales are sliding, the brand’s stock still posted a gain, closing at 0.6 percent to $97.71.

"Consumer needs and preferences have changed and McDonald's current performance reflects the urgent need to evolve with today's consumers, reset strategic priorities and restore business momentum," the company said in a statement.

In other parts, monthly sales for the Asia/Pacific, Middle East and Africa regions are also down 4.4 percent. Europe, however, showed a positive increase, posting a hike of 0.7 percent.

"While changes are in the works, we cannot identify a near-term catalyst to spur sales," says Sterne Agee analyst Lynne Collier in a note to investors.

February’s results followed a critical “Turnaround Summit” where executives gathered together with franchisees in Las Vegas to discuss operational plans moving forward. It was during this conference the company announced that the use of human antibiotics would end over the next two years.

Read more by clicking here.